AOP Orphan Pharmaceuticals AG
A-1160 Wien
Wilhelminenstraße
Vienna
91/ II f / B4
Tel: 43-1-5037244-22
Fax: 43-1-5037244-61
Website: http://www.aoporphan.at/index.php?id=22&L=2
Email: office@aoporphan.at
28 articles about AOP Orphan Pharmaceuticals AG
-
AOP Orphan Pharmaceuticals AG Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
10/10/2013
-
AOP Orphan Pharmaceuticals AG Spins Off Its Stake in Activartis Biotech GmbH and Outlines Business Strategy
6/17/2013
-
AOP Orphan Pharmaceuticals AG Release: Essential Thrombocythemia (ET) – Convincing Data of ANAHYDRET Study Now Published
3/18/2013
-
AOP Orphan Pharmaceuticals AG Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)
12/10/2012
-
Shield Signs Agreement for ST10-021 with AOP Orphan Pharmaceuticals AG
11/1/2010
-
AOP Orphan Pharmaceuticals AG and Lantibio Inc. Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
3/7/2007
-
Novelix Pharmaceuticals Inc. Announces Licensing of Cancer Compound to AOP Orphan Pharmaceuticals AG
2/26/2007
-
AOP Orphan Pharmaceuticals And Lantibio, Inc. Announce A Licensing And Commercialization Agreement For Moli1901 In Cystic Fibrosis
5/27/2004